Small Cap Feast
Small Cap Feast – 12 September 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019
Rumours and Speculation
Press reports that Georgina Energy will join the standard list at the end of this month. Georgina is acquiring the EP127 licence in the Northern Territory, Australia, which has significant helium potential. It is raising up to £10m
LiDCO Group Plc (LID) 4.25p £10.38m
Today, LiDCO announces that the Company has signed a variation agreement to its existing commercial collaboration with CNSystems Medizintechnik AG, Graz, Austria providing LiDCO with access to CNS’ latest continuous non-invasive blood pressure monitoring software.
The main improvements with this latest software Include:
Faster set-up, significantly reducing the time to start monitoring, meaning that clinicians can be monitoring their patients in less than a minute
Sensor size assistant, automatically recognising if an incorrect sensor size is attached, ensuring an error-free application that gives notice to the user if finger sensor size does not fit
Improved signal optimisation, for more reliable short and long term blood pressure tracking.
Ovoca Bio (OVB) 12.5p £9.2m
Ovoca Bio, a biopharmaceutical company focused on identifying and developing novel therapeutics targeting the large unmet needs in the treatment of female sexual dysfunction, today announces that a Marketing Authorisation application for BP-101, a novel synthetic peptide administered through a nasal spray, has been filed by its subsidiary, IVIX LLC, with the Russian Ministry of Health.
IVIX submitted the BP-101 MA application for the treatment of hypoactive sexual desire disorder, a condition characterized by a distressing lack or loss of sexual desire, in premenopausal women. The MA application is based on data from two Phase 1 studies, a Phase 2a study and the pivotal Phase 3 study completed earlier this year, conducted in Russia, which establish the safety and efficacy of BP-101 in the proposed indication.
HML Holdings (HMLH) 33.5p £15.35m
HML Holdings plc , a leading provider of property management, insurance and ancillary services to residential property blocks, announced the acquisition of Thornes Chartered Surveyors, a property management business with offices in Luton, on 11 September 2019.
HML has purchased the business and assets of TCS for £376,000 cash consideration, satisfied from HML’s existing facilities. The transaction includes additional performance related retention payments of up to £94,000 in total which will be subject to the achievement of certain criteria and will be payable 12 months and 24 months from the acquisition date.
TCS was established 1896 and has been operating as a standalone property management business for block and lettings under the leadership its current owner, Andrew Randall. The business has annual revenues of £370,000 and now manages over 70 blocks for 1,300 mainly leasehold property owners in addition to over 170 properties managed as let properties.
Focusrite (TUNE) 525p £289m
Focusrite Plc, the global music and audio company supplying hardware and software products used by professional and amateur recording engineers and musicians, updates the market on another successful year in which revenue and profits have grown strongly.
The Company expects revenue for the financial year ending 31 August 2019, to be ahead of market expectations at approximately £84m, up from £75.1m last year. This growth comprises an increase of approximately 10% for the existing business (c6% on a constant currency basis) and approximately six weeks of revenue for ADAM Audio, a German studio monitor company, which was acquired on 16 July 2019 for a total consideration of £16.2m in cash. Margins have remained consistent with the prior year and as a result EBITDA is also expected to be ahead of market expectations.
Aggregated Micro (AMPH) 73.5p £46.5m
Aggregated Micro Power Holdings plc, trading as AMP Clean Energy, the specialist provider of distributed heat, power and renewable fuels, announces a further trading update in respect of the twelve months ended 31 March 2019.
It is expected to show revenues and income of £50m and an EBITDA loss in the region of £1.3m.
During the last two years, the Wood Fuels business underwent a transformative restructuring to bring all operations into a single management and brand platform which has further consolidated its market leading position. This has resulted in significant non-recurring costs from depot closures, office relocations and redundancies; all of which has been expensed through the profit and loss account.
Diversified Gas & Oil (DGOC) 113.5p £739m
Diversified Gas & Oil PLC, the U.S. based owner and operator of natural gas, natural gas liquids and oil wells as well as midstream assets, provides the following update of their proposed Move to Main Market
The Board confirms that following its robust evaluation of the matter, the Company is formally pursuing a move to the Premium segment of the Main Market of the London Stock Exchange, which it expects to complete following the publication of its full-year results issued in Q1 2020, subject to the approval of the UK’s Financial Conduct Authority. The Company will announce further details as appropriate.
Agronomics (ANIC) 9p £10.24m
The Board of Agronomics announced that investee company, Insilico Medicine Cayman Topco has completed its US$37m Series B financing led by Qiming Venture Partners, along with Juvenescence, Eight Roads, Longevity Vision Fund, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, BOLD Capital Partners and other prominent investors in the field of longevity. Insilico is a pioneer in the application of next-generation artificial intelligence to drug discovery, biomarker development and ageing research.
UK Oil & Gas (UKOG) 1.23p £76m
UK Oil & Gas announced that final site works to accommodate the arrival of the rig to drill the new Horse Hill-2/2z (“HH-2/2z”) Portland horizontal well commenced at 1200 hrs, Friday 30 August and were completed yesterday. Test production from the Horse Hill-1 (“HH-1”) Kimmeridge oil pool was temporarily shut-in to permit oil storage tanks and flowlines to be relocated to enable safe simultaneous drilling and HH-1 testing operations. Kimmeridge test oil production has now resumed and will continue until the rig arrives, when a further short shut-in will occur to enable the HH-2/2z drilling set-up to be assembled.
Biome Technologies (BIOM) 335p £8.3m
Biome Technologies plc, a leading bioplastics and radio frequency technology business, announced that it has conditionally raised approximately £1.3m (before expenses) at a price of 300 pence per share to fund Biome Bioplastics’ growth and development including Growth capital needs for several bioplastics projects that are scaling up and will drive a significant increase in revenues over the next 18 months .
PROVIDENCE RES. (PVR) 5.4p £32.87m
Providence Resources, the Irish based energy company announces that it has conditionally raised approximately US$3.76m investors at a price of £0.051 . The proceeds of the Placing will only provide working capital in respect of general, administrative and licence operating costs for the period to the beginning of February 2020. Accordingly, the Board is currently undertaking a strategic review of the options available to the Company on future financing alternatives. Timing of $9m loan remains unclear. “ The materiality of both our portfolio and investment in offshore Ireland remains, and the Board remain focused on realising value”.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.